Mylotarg™ (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

Mylotarg™ (Wyeth‐Ayerst Laboratories, St. Davids, PA) is the brand name for a calicheamicin‐conjugated humanized anti‐CD33 monoclonal antibody (gemtuzumab ozogamicin, CMA‐676) and has been approved recently for the treatment of a subset of elderly patients who have relapsed acute myeloid leukemia (AML). Mylotarg is associated with an incidence of approximately 20% Grade 3 or 4 hyperbilirubinemia and liver transaminitis in this patient population. Hepatic venoocclusive disease (VOD) has been reported in patients who have undergone stem cell transplantation (SCT) after Mylotarg therapy. Outside of the SCT setting, VOD has been associated very rarely with cytotoxic therapy.

[1]  M. Berger,et al.  Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody‐Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse , 2001, Journal of clinical pharmacology.

[2]  I. Bernstein,et al.  Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. , 2001, Blood.

[3]  T. Barbui,et al.  Defibrotide for the treatment of hepatic veno‐occlusive disease: results of the European compassionate‐use study , 2000, British journal of haematology.

[4]  J. Jurcic.  Antibody therapy of acute myelogenous leukemia. , 2000, Cancer biotherapy & radiopharmaceuticals.

[5]  S. Chan,et al.  Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  P. Dedon,et al.  DNA bending is a determinant of calicheamicin target recognition. , 2000, Biochemistry.

[7]  N. Nicaise,et al.  Acute radiation-induced hepatic injury: evaluation by triphasic contrast enhanced helical CT. , 2000, The British journal of radiology.

[8]  I. Bernstein.  Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate , 2000, Leukemia.

[9]  G. Kanel,et al.  Support of sinusoidal endothelial cell glutathione prevents hepatic veno‐occlusive disease in the rat , 2000, Hepatology.

[10]  D. Scheinberg,et al.  Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  J. M. Merino,et al.  VENO-OCCLUSIVE DISEASE OF THE LIVER ASSOCIATED WITH THIOPURINES IN A CHILD WITH ACUTE LYMPHOBLASTIC LEUKEMIA , 2000, Pediatric hematology and oncology.

[12]  E. Estey,et al.  Low incidence of hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (mylotarg™, cma-676) , 2000 .

[13]  M. A. van den Bosch,et al.  MR imaging findings in two patients with hepatic veno-occlusive disease following bone marrow transplantation , 2000, European radiology.

[14]  F. Appelbaum,et al.  Antibody-targeted therapy for myeloid leukemia. , 1999, Seminars in hematology.

[15]  D. Scheinberg,et al.  A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  I. Bernstein,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate , 2017 .

[17]  G. Gaedicke,et al.  Targeted therapy with a novel enediyene antibiotic calicheamicin theta(I)1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma. , 1998, Cancer research.

[18]  N. Callander,et al.  Ursodiol Prophylaxis against Hepatic Complications of Allogeneic Bone Marrow Transplantation , 1998, Annals of Internal Medicine.

[19]  D. Scheinberg,et al.  Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  P. Sonneveld,et al.  Color-flow imaging sonography of portal and hepatic vein flow to monitor fibrinolytic therapy with r-TPA for veno-occlusive disease following myeloablative treatment , 1998, Bone Marrow Transplantation.

[21]  K. Nicolaou,et al.  Supercoiling affects the accessibility of glutathione to DNA-bound molecules: positive supercoiling inhibits calicheamicin-induced DNA damage. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  A. Varan,et al.  Veno-occlusive disease-like hepatotoxicity in two children receiving chemotherapy for Wilms' tumor and clear cell sarcoma of kidney. , 1998, Pediatric hematology and oncology.

[23]  S. Donaldson,et al.  Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma , 1997, Cancer.

[24]  D. Patel,et al.  Solution structure of the calicheamicin gamma 1I-DNA complex. , 1997, Journal of molecular biology.

[25]  S. Bearman,et al.  The syndrome of hepatic veno-occlusive disease after marrow transplantation. , 1995, Blood.

[26]  W. Wrasidlo,et al.  Regulation of apoptosis in leukemic cells by analogs of dynemicin A. , 1994, Bioorganic & medicinal chemistry.

[27]  P. Dedon,et al.  Enediyne-mediated DNA damage in nuclei is modulated at the level of the nucleosome. , 1994, The Journal of biological chemistry.

[28]  M. Yeong,et al.  Actinomycin D Associated Hepatic Veno-Occlusive Disease — A Report Of 2 Cases , 1994, Pathology.

[29]  E. Favaloro.  Differential expression of surface antigens on activated endothelium , 1993, Immunology and cell biology.

[30]  G. Anderson,et al.  Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Wallace,et al.  Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. , 1993, Cancer research.

[32]  J. Vogel,et al.  Grossly Abnormal Liver‐Spleen Scan in a Patient with Veno‐occlusive Disease of the Liver that Normalized Completely on Follow‐up , 1993, Clinical nuclear medicine.

[33]  J. Xu,et al.  Exclusive production of bistranded DNA damage by calicheamicin. , 1993, Biochemistry.

[34]  G. McDonald,et al.  Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients , 1993, Annals of Internal Medicine.

[35]  K. Goa,et al.  Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. , 1993, Drugs.

[36]  N. Callander,et al.  Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients. , 1992, Bone marrow transplantation.

[37]  T. Greenough,et al.  Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  G. Ellestad,et al.  Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. , 1988, Science.

[39]  L. Grochow,et al.  VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION , 1987, Transplantation.

[40]  H. Deeg,et al.  Induction of hepatic veno-occlusive disease in dogs. , 1987, The American journal of pathology.

[41]  Winton Ef,et al.  High incidence of veno-occlusive disease related to indicine N-oxide in the treatment of refractory adult acute leukemia. , 1986 .

[42]  P. McCue,et al.  High incidence of veno-occlusive disease related to indicine N-oxide in the treatment of refractory adult acute leukemia. , 1986, Cancer treatment reports.

[43]  R. Paschke,et al.  Pathophysiological aspects of dacarbazine-induced human liver damage. , 1985, Hepato-gastroenterology.

[44]  Pankaj Sharma,et al.  THE CLINICAL COURSE OF 53 PATIENTS WITH VENOCCLUSIVE DISEASE OF THE LIVER AFTER MARROW TRANSPLANTATION , 1985, Transplantation.

[45]  Pankaj Sharma,et al.  Venocclusive Disease of the Liver after Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing Factors , 1984, Hepatology.

[46]  J. Naiman,et al.  Veno‐occlusive disease of the liver in children following chemotherapy for acute myelocytic leukemia , 1983, Cancer.

[47]  M. Satti,et al.  6-Thioguanine as a cause of toxic veno-occlusive disease of the liver , 1982, Journal of clinical pathology.

[48]  D. Maneval,et al.  Hepatic veno-occlusive disease caused by 6-thioguanine. , 1982, Annals of internal medicine.

[49]  P. Griner,et al.  Veno-occlusive disease of the liver after chemotherapy of acute leukemia. Report of two cases. , 1976, Annals of internal medicine.

[50]  K. Tınaztepe,et al.  Veno-occlusive disease of the liver. , 1967, The Turkish journal of pediatrics.